Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
513.72
-3.67 (-0.71%)
At close: May 1, 2026, 4:00 PM EDT
511.00
-2.72 (-0.53%)
After-hours: May 1, 2026, 4:58 PM EDT
Madrigal Pharmaceuticals Employees
Madrigal Pharmaceuticals had 915 employees as of December 31, 2025. The number of employees increased by 387 or 73.30% compared to the previous year.
Employees
915
Change (1Y)
387
Growth (1Y)
73.30%
Revenue / Employee
$1,047,435
Profits / Employee
-$315,064
Market Cap
11.78B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 915 | 387 | 73.30% |
| Dec 31, 2024 | 528 | 152 | 40.43% |
| Dec 31, 2023 | 376 | 284 | 308.70% |
| Dec 31, 2022 | 92 | 21 | 29.58% |
| Dec 31, 2021 | 71 | 29 | 69.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Jazz Pharmaceuticals | 2,890 |
| Ionis Pharmaceuticals | 1,402 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
| Axsome Therapeutics | 925 |
| BridgeBio Pharma | 839 |
| Arrowhead Pharmaceuticals | 711 |
MDGL News
- 11 days ago - Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026 - GlobeNewsWire
- 11 days ago - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Madrigal Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - Madrigal Pharmaceuticals Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH - PRNewsWire
- 2 months ago - Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs - GlobeNewsWire